GABA B receptor subtypes are based on the subunit isoforms GABA B1a and GABA B1b , which associate with GABA B2 subunits to form pharmacologically indistinguishable GABA B(1a,2) and GABA B(1b,2) receptors. Studies with mice selectively expressing GABA B1a or GABA B1b subunits revealed that GABA B(1a,2) receptors are more abundant than GABA B(1b,2) receptors at glutamatergic terminals. Accordingly, it was found that GABA B(1a,2) receptors are more efficient than GABA B(1b,2) receptors in inhibiting glutamate release when maximally activated by exogenous application of the agonist baclofen. Here, we used a combination of genetic, ultrastructural and electrophysiological approaches to analyze to what extent GABA B(1a,2) and GABA B(1b,2) receptors inhibit glutamate release in response to physiological activation. We first show that at hippocampal mossy fiber (MF)-CA3 pyramidal neuron synapses more GABA B1a than GABA B1b protein is present at presynaptic sites, consistent with the findings at other glutamatergic synapses. In the presence of baclofen at concentrations Ն1 M, both GABA B(1a,2) and GABA B(1b,2) receptors contribute to presynaptic inhibition of glutamate release. However, at lower concentrations of baclofen, selectively GABA B(1a,2) receptors contribute to presynaptic inhibition. Remarkably, exclusively GABA B(1a,2) receptors inhibit glutamate release in response to synaptically released GABA. Specifically, we demonstrate that selectively GABA B(1a,2) receptors mediate heterosynaptic depression of MF transmission, a physiological phenomenon involving transsynaptic inhibition of glutamate release via presynaptic GABA B receptors. Our data demonstrate that the difference in GABA B1a and GABA B1b protein levels at MF terminals is sufficient to produce a strictly GABA B1a -specific effect under physiological conditions. This consolidates that the differential subcellular localization of the GABA B1a and GABA B1b proteins is of regulatory relevance.
Introduction
GABA B receptors are the G-protein coupled receptors for ␥-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the CNS. They have been implicated in a variety of disorders, including cognitive impairments, anxiety, depression and epilepsy (Calver et al., 2002; Bettler et al., 2004) . Presynaptic GABA B receptors inhibit neurotransmitter release via the inhibition of Ca 2ϩ channels and second-messenger-mediated effects downstream of Ca 2ϩ entry (Scanziani et al., 1992; Jarolimek and Misgeld, 1997; Yamada et al., 1999; Sakaba and Neher, 2003) . They are commonly divided into autoreceptors and heteroreceptors depending on whether they control the release of GABA or other neurotransmitters, respectively. Postsynaptic GABA B receptors activate Kir3-type K ϩ channels, which induces slow inhibitory potentials and mediates shunting inhibition (Lüscher et al., 1997) . The physiological functions of GABA B receptors have been mostly inferred from electrophysiological experiments in which the receptors were pharmacologically activated by exogenous application of the agonist baclofen. Physiological activation of GABA B receptors usually requires strong stimulus intensities, suggesting that pooling of synaptically released GABA is required to activate them (Isaacson et al., 1993; Scanziani, 2000) . This agrees with ultrastructural data demonstrating that most GABA B receptors are located distant from release sites (Ló pez-Bendito et al., 2004; Lacey et al., 2005; Kulik et al., 2006) . A tonic activation of GABA B receptors through ambient GABA was also observed, which may partly explain their predominantly extrasynaptic lo-calization as well (Lei and McBain, 2003; Price et al., 2005; Liu et al., 2006) . GABA B receptors are heteromers composed of GABA B1 and GABA B2 subunits (Calver et al., 2002; Bettler et al., 2004) . The only molecular distinction in the GABA B receptor system is based on the subunit isoforms GABA B1a and GABA B1b , which differ in their ectodomains by a pair of "sushi domains" that are unique to GABA B1a (Hawrot et al., 1998) . Heteromeric GABA B(1a,2) and GABA B(1b,2) receptors do not exhibit pharmacological differences and couple to the same effector systems in transfected cells. To address the reason for the existence of two receptor subtypes we generated GABA B1a Ϫ/Ϫ (1a Ϫ/Ϫ ) and GABA B1b Ϫ/Ϫ (1b Ϫ/Ϫ ) mice, which express either one or the other GABA B1 subunit isoform. Pharmacological studies with these mice suggest that GABA B1a and GABA B1b differentially influence synaptic functions, primarily as a result of their distinct distributions to axonal and dendritic compartments . In principle, since GABA B1a and GABA B1b subunits are independently regulated at the transcriptional level (Steiger et al., 2004) , this allows for dynamically adjustable GABA B signaling at axonal and dendritic effectors. However, to clearly establish a regulatory significance for GABA B receptor subtypes, it needs to be demonstrated that they not only yield differential effects in response to pharmacological activation, but also in response to physiological activation (Huang, 2006) . A physiological phenomenon proposed to rely on the endogenous activation of GABA B heteroreceptors is heterosynaptic depression (Isaacson et al., 1993; Vogt and Nicoll, 1999; Chandler et al., 2003) . Here, we studied heterosynaptic depression at MF-CA3 pyramidal neuron synapses to address to what extent the two GABA B receptor subtypes inhibit glutamate release in response to activation by synaptically released GABA.
Materials and Methods

Mutant mouse strains. The generation of 1a
Ϫ/Ϫ and 1b Ϫ/Ϫ mice was described previously (Vigot et al., 2006) . For control experiments we additionally used GABA B1 -deficient (1 Ϫ/Ϫ ) mice that completely lack GABA B1 protein (Schuler et al., 2001) . Homozygous mutant mice and wild-type (WT) littermate mice were obtained by breeding heterozygous mice on a pure inbred BALB/c genetic background. All animal experiments were subjected to institutional review and approved by the veterinary office of Basel-Stadt.
Pre-embedding immunocytochemistry and quantitative analysis. Preembedding GABA B1 immunogold labeling and electron microscopy was done as described, using affinity-purified guinea pig polyclonal antiserum B62 raised against the C-terminal 103 amino acid residues of GABA B1a and GABA B1b (Kulik et al., 2006) . Light microscopy confirmed that the B62 antiserum immunostains WT, 1a Ϫ/Ϫ , and 1b Ϫ/Ϫ hippocampal sections, but not 1 Ϫ/Ϫ sections (data not shown). Preembedding electron microscopy showed a reduction of the immunogold particle density by 86% in 1 Ϫ/Ϫ hippocampal sections compared with WT sections, which agrees well with earlier control experiments where the reduction of immunogold particles in 1 Ϫ/Ϫ sections was 88% (Vigot et al., 2006) . Immunogold particles that nonspecifically labeled 1 Ϫ/Ϫ sections were approximately equally distributed over presynaptic and postsynaptic membranes, as described (Vigot et al., 2006) . Preembedding electron microscopy of WT, 1a Ϫ/Ϫ , and 1b Ϫ/Ϫ mice (8 -12 weeks old, n ϭ 3 per genotype) included the analysis of 10 different MF boutons per mouse. MF boutons were identified by their large size (3-6 m in diameter), the dense packing with synaptic vesicles and their contacts with at least 2 spines. For each MF bouton we examined at least 4 consecutive sections. Only immunogold particles at the plasma membrane (closer than 20 nm) of morphologically identifiable large MF boutons and their postsynaptic structures were analyzed. The postsynaptic distribution of GABA B1 protein relative to asymmetrical, putative glutamatergic synapses was determined by measuring the distance between each immunogold particle and the edge of the nearest synapse along the surface of spines. Immunogold particles were allocated to 60 nm wide bins, followed by calculating the relative abundance in each bin. The experimenter was blind to the genotype of the mice.
Immunoblot quantification. The ratio of GABA B1a to GABA B1b protein in the CA3 region of the hippocampus was determined by immunoblot analysis using rabbit polyclonal GABA B1 antiserum Ab174.1 raised against the C-terminal domain of GABA B1a and GABA B1b (Vigot et al., 2006) . Scanned immunoblots were quantified using Scion Image software (Scion).
Slice preparation and electrophysiology. Hippocampal slices were prepared from 21-to 35-d-old mice using standard procedures (Vigot et al., 2006) . Parasagittal slices (300 m thick) were cut in ice-cold artificial CSF (ACSF) containing (in mM) 124 NaCl, 2.7 KCl, 1.3 MgCl 2 , 2 CaCl 2 , 1.24 NaH 2 PO 4 , 26 NaHCO 3 , 18 glucose, 2.25 ascorbate, pH 7.3, equilibrated with 95% O 2 /5% CO 2 . Slices were kept in oxygenated ACSF at 35°C for at least 45 min before recording. Visualized whole-cell patchclamp recording was used to investigate presynaptic and postsynaptic GABA B receptor functions. Holding currents and excitatory synaptic responses were recorded at 30Ϫ32°C from the somata of CA3 pyramidal neurons visualized using an infrared-sensitive camera (Till Photonics) and differential interference contrast optics (BX51WI; Olympus). Drugs were applied by superfusion into the recording chamber.
EPSCs were recorded with electrodes (ϳ5 M⍀) filled with a solution containing (in mM): 140 Cs-gluconate, 10 HEPES, 10 phosphocreatine, 5 QX-314, 4 Mg-ATP, 0.3 Na-GTP, at pH 7.25 with CsOH, 285 mOsm. EPSCs were elicited by voltage pulses (100 s, 2-5 V stimuli) delivered through a bipolar Pt-Ir electrode (25 m in diameter) placed in the stratum lucidum. MF EPSCs were identified by the presence of a frequency-dependent short-term facilitation. EPSCs were measured at Ϫ70 mV in the presence of 100 M picrotoxin. Presynaptic GABA B and adenosine receptors were activated by bath application of baclofen (50 M) and adenosine (100 M), respectively. GABA B receptors were inhibited by application of the antagonist CGP54626A (1 M). For the presynaptic dose-response experiments, baclofen at different concentrations (0.1, 1 and 50 M) was bath applied for 5 min at 10 min intervals.
To record postsynaptic Kir3-type K ϩ currents, patch pipettes were filled with a solution containing (in mM): 140 K-gluconate, 5 HEPES, 2 MgCl 2 , 1.1 EGTA, 2 Na 2 -ATP, 5 phosphocreatine, 0.6 Tris-GTP, at pH 7.25 with KOH, 285 mOsm. Kir3-type K ϩ currents induced by baclofen (100 M) or adenosine (100 M) were elicited at Ϫ50 mV in the presence of tetrodotoxin (TTX, 1 M). For concentration-response experiments we applied baclofen solutions (0.3 -100 M) for 30 s using the fast gravitation driven application system WAS-02 (Dittert et al., 2006) . The inner diameter of the application tube was 300 m. The distance between the mouth of the tube and the soma of the neuron was ϳ400 m. GABA A -and GABA B -mediated IPSCs (early and late IPSCs, respectively) were recorded with a solution containing (in mM) 124 K-gluconate, 16 KCl, 5 HEPES, 2 MgCl 2 , 1.1 EGTA, 2 MgATP, 3 Na 3 GTP, pH 7.25. IPSCs were elicited at Ϫ60 mV by 100 s pulses (3 stimuli at 100 Hz) in the presence of kynurenic acid (2 mM), DNQX (10 M), naloxone (10 M) and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 1 M) to block glutamate, opioid and A1 adenosine receptors.
GABA B -mediated heterosynaptic depression at MF synapses was studied by recording field EPSPs (fEPSPs) in the stratum lucidum (Vogt and Nicoll, 1999; Chandler et al., 2003) . The occurrence of heterosynaptic depression is not critically dependent on the temperature, as no significant differences were previously observed between experiments at room temperature and at 34°-36°C (Vogt and Nicoll, 1999) . We therefore recorded fEPSPs at room temperature, using low resistance glass pipettes filled with ACSF. Stimulating electrodes filled with ACSF were positioned into the dentate gyrus, and MF responses elicited by 100 s pulses. MF-evoked fEPSPs were identified through their characteristic shortterm plasticity and their sensitivity to the group II mGluR agonist (2S,2ЈR,3ЈR)-2-(2Ј,3Ј-dicarboxycyclopropyl)-glycine (DCG-IV, 2 M) (Kamiya et al., 1996) . Heterosynaptic depression was measured in the presence of naloxone (10 M) and DPCPX (1 M) to avoid interference from presynaptic opioid and A1 adenosine receptors, respectively (Weisskopf et al., 1993; Manzoni et al., 1994; Cunha, 2008) . Under these con-ditions heterosynaptic depression was significantly reduced by the GABA B antagonist CGP54626A (2 M). Data were acquired with an Axopatch 200B (Molecular Devices), filtered at 2 kHz and digitized at 10 kHz using a Digidata 1322A Interface (Molecular Devices) driven by pClamp 9.2 software (Molecular Devices). Whole-cell currents and field potentials were analyzed using Clampfit 9.2 software (Molecular Devices). Baclofen and CGP54626A were from Novartis Pharma. Naloxone, DNQX, DPCPX, and DCG-IV were from Tocris Cookson, TTX from Latoxan. All other reagents were from Sigma-Aldrich. Most recordings were made and analyzed in blind. All values are means Ϯ SEM.
Results
Presynaptic versus postsynaptic distribution of GABA B1 isoforms at MF-CA3 pyramidal neuron synapses Before addressing the contribution of GABA B receptor subtypes to presynaptic inhibition at MF terminals, we determined the GABA B1a and GABA B1b distribution at presynaptic and postsynaptic sites. We performed pre-embedding immunogold electron microscopy in the hippocampal CA3 stratum lucidum of WT, 1a Ϫ/Ϫ , and 1b Ϫ/Ϫ mice, using a pan GABA B1 antibody recognizing GABA B1a and GABA B1b . MF-CA3 pyramidal neuron synapses within large MF boutons were identified at the ultrastructural level as asymmetrical synapses at the spines of pyramidal neurons. In WT mice GABA B1 protein was present at presynaptic and postsynaptic elements of MF-CA3 pyramidal neuron synapses ( Fig. 1 A-C) . 19.3 Ϯ 10.7% of all counted immunogold particles were localized at synaptic and extrasynaptic sites of MF boutons, while the remaining 80.7 Ϯ 10.7% were associated with spines and proximal dendritic shafts of pyramidal neurons ( Fig. 1 J) . A similar distribution was reported for the MF-CA3 pyramidal neuron synapse in rat brain (Kulik et al., 2003) . In 1a Ϫ/Ϫ mice, 92.7 Ϯ 2.1% of all immunogold particles were observed on spines and dendritic shafts of pyramidal neurons, indicating that GABA B1b protein mainly localizes to postsynaptic elements ( Fig.  1 
D-F, J ). In contrast, in 1b
Ϫ/Ϫ mice 55.3 Ϯ 4.6% of all immunogold particles were associated with the presynaptic membrane of MF boutons, demonstrating that GABA B1a protein is slightly more abundant at presynaptic elements ( Fig. 1G-J ) . Strikingly, the ratios of pre-to postsynaptic immunogold particles in the different genotypes were similar at MF-CA3 pyramidal neuron synapses (ratios for WT: 0.24, 1a Ϫ/Ϫ : 0.08, 1b Ϫ/Ϫ : 1.24) and CA3-CA1 synapses (ratios for WT: 0.31, 1a Ϫ/Ϫ : 0.17, 1b Ϫ/Ϫ : 1.61; (Vigot et al., 2006) ). Quantification from immunoblots indicates an overall GABA B1a to GABA B1b protein ratio of 0.60 Ϯ 0.04 (n ϭ 4 mice, p Ͻ 0.01, one sample Student's t test) in the CA3 region of the hippocampus (data not shown). Considering this ratio and the synaptic distribution of immunogold particles, we approximately estimate that the GABA B1a to GABA B1b protein ratio at presynaptic and postsynaptic sites is 4.5:1 and 1:3.5, respectively. Importantly, we did not observe any MF boutons and associated postsynaptic spines without specific immunogold particle labeling, suggesting that most, if not all, MF synapses express GABA B receptors.
Subsynaptic distribution of GABA B1 isoforms in presynaptic and postsynaptic elements of MF-CA3 pyramidal neuron synapses
We next studied the distribution of GABA B1 protein relative to synaptic specializations at MF-CA3 pyramidal neuron synapses. We first determined the percentage of GABA B1 immunogold particles in MF boutons that are present at presynaptic membranes opposite to postsynaptic densities (PSDs). In WT and 1b Ϫ/Ϫ mice 22% of all presynaptic GABA B1 immunogold particles were localized opposite to PSDs and 78% at extrasynaptic membranes (Fig. 2 A) . In 1a Ϫ/Ϫ mice 11% of all immunogold particles in MF boutons were found opposite to PSDs, demonstrating that the GABA B1b protein distribution is significantly shifted toward extrasynaptic sites. Considering an overall GABA B1a to GABA B1b protein ratio of 0.60 (see above), we approximately estimate a GABA B1a to GABA B1b protein ratio of 9:1 in the active zones of MF boutons. We additionally analyzed the distribution of GABA B1 protein in dendritic spines of CA3 pyramidal neurons. Independent of the genotype we rarely observed immunogold particles in the PSD, likely because the pre-embedding technique limits penetration of immunoreagents into the PSD (Kulik et al., 2002 (Kulik et al., , 2003 . However, we did not observe any significant differences between WT, 1a Ϫ/Ϫ , and 1b Ϫ/Ϫ mice in the distribution of GABA B1 immunoparticles at perisynaptic and extrasynaptic dendritic sites (Fig. 2 B) . Of note, ϳ20% of all immunoparticles were found within 60 nm from the edge of the PSDs at perisynaptic sites.
GABA B(1a,2) receptors are more efficient than GABA B(1b,2) receptors in inhibiting glutamate release in response to pharmacological activation We used whole-cell patch-clamp recording in slice preparations from WT, 1a
Ϫ/Ϫ , and 1b Ϫ/Ϫ mice to examine to what extent GABA B(1a,2) and GABA B(1b,2) receptors can inhibit glutamate release in response to a maximally active concentration of the agonist baclofen. Stimulation of MFs in the stratum lucidum induces EPSCs in CA3 pyramidal neurons that are reduced in amplitude by activation of GABA B heteroreceptors. A high concentration of baclofen (50 M) reduced EPSC amplitudes in all three genotypes (Fig. 3 A, B) . However, baclofen was significantly less effective in inhibiting release in 1a Ϫ/Ϫ mice than in WT and 1b Ϫ/Ϫ mice. As a control, activation of adenosine A1 receptors by adenosine inhibited glutamate release in all three genotypes to a similar extent (Fig. 3 A, B) . We tested whether lower concentrations of baclofen (0.1, 1 M) activate GABA B(1a,2) heteroreceptors without engaging GABA B(1b,2) heteroreceptors (Fig. 3C) . This was the case at 0.1 M, at which concentration baclofen reduced glutamate release in WT and 1b Ϫ/Ϫ mice but not in 1a Ϫ/Ϫ mice (Fig. 3C) . Altogether, the electrophysiological data therefore parallel the ultrastructural data described above (Figs. 1, 2) . They support that the number of GABA B(1a,2) heteroreceptors in 1b Ϫ/Ϫ mice is sufficient to produce a maximal level of presynaptic inhibition (similar to WT), while GABA B(1b,2) heteroreceptors in 1a Ϫ/Ϫ mice are limiting and consequently produce submaximal inhibition. At low concentrations of baclofen, only GABA B(1a,2) heteroreceptors appear to be present in sufficient numbers to inhibit glutamate release.
Recent reports show that certain presynaptic GABA B receptors can be tonically activated by ambient GABA (Jensen et al., 2003; Lei and McBain, 2003; Liu et al., 2006) . Bath application of the GABA B antagonist CGP54626A had no effect on the amplitudes of evoked EPSCs in WT, 1a Ϫ/Ϫ , and 1b Ϫ/Ϫ mice (Fig.  3 D, E) . This demonstrates that under our experimental conditions ambient GABA does not tonically activate GABA B heteroreceptors at MF boutons.
GABA B(1a,2) and GABA B(1b,2) receptors activate postsynaptic K ؉ channels to a similar extent in response to pharmacological activation We next studied the relative contributions of GABA B1a and GABA B1b isoforms to the formation of functional somatodendritic GABA B receptors on CA3 pyramidal neurons, using somatic whole-cell patch-clamp recordings in slices. Somatoden-dritic GABA B receptors induce a late IPSC by activating Kir3-type K ϩ channels (Lüscher et al., 1997) . At a holding potential of Ϫ50 mV and at a physiological concentration of extracellular K ϩ , pharmacological activation with a maximally active concentration of baclofen (100 M) elicited smaller outward K ϩ currents in CA3 pyramidal cells of 1a Ϫ/Ϫ and 1b Ϫ/Ϫ mice compared with WT mice (Fig. 4 A, B) . The maximal K ϩ currents induced by baclofen were similar in 1a Ϫ/Ϫ and 1b Ϫ/Ϫ mice, thus showing that GABA B(1b,2) and GABA B(1a,2) receptors activate K ϩ channels to a similar extent. Pharmacological activation of adenosine A1 receptors, which converge on the same Kir3-type K ϩ channels (Lüscher et al., 1997) , induced similar outward currents in all genotypes (Fig. 4 A, B) . This indicates that the expression levels of 4 the edge of the presynaptic membrane specialization and at perisynaptic and extrasynaptic dendritic sites. D-F, In 1a Ϫ/Ϫ mice, immunogold particles were almost exclusively found in postsynaptic elements, predominantly at perisynaptic and extrasynaptic sites. In rare cases, immunogold particles were also observed in MF boutons (E).
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Ϫ/Ϫ mice, immunogold particles were observed in presynaptic and postsynaptic elements. Immunogold particles were frequently found at the presynaptic membrane specialization of MF boutons. J, Quantitative analysis of presynaptic versus postsynaptic immunogold particles in WT, 1a Ϫ/Ϫ , and 1b Kir3-type K ϩ channels are not altered as a consequence of the lack of GABA B1 isoform proteins. We tested whether lower concentrations of baclofen possibly generate distinct K ϩ outward currents in 1a
and 1b Ϫ/Ϫ mice, which was not the case (Fig. 4C) . A reduction of K ϩ current amplitudes in 1a Ϫ/Ϫ and 1b Ϫ/Ϫ mice was only observed at high concentrations of baclofen (100 M), while at lower concentrations (Յ 10 M) the K ϩ current amplitudes were similar in all genotypes (Fig.  4C ). Since at all concentrations of baclofen the GABA B -induced K ϩ currents in 1a
and 1b Ϫ/Ϫ mice were similar, this suggests that GABA B(1b,2) and GABA B(1a,2) receptors are able to activate K ϩ channels to a similar extent.
GABA B(1a,2) but not GABA B(1b,2) receptors inhibit glutamate release in response to physiological activation
To address to what extent the two GABA B receptor subtypes contribute to physiological inhibition of glutamate release at MF terminals we examined heterosynaptic depression in WT, 1a Ϫ/Ϫ , and 1b Ϫ/Ϫ mice. GABA B receptor-mediated heterosynaptic depression of MF transmission has been studied using fEPSP recordings and relies on the activation of GABA B heteroreceptors by GABA released from neighboring interneurons (Vogt and Nicoll, 1999; Chandler et al., 2003) . We first verified that the stimulating electrode in the dentate gyrus evokes fEPSPs with properties consistent with MF transmission. MF synaptic responses were identified by the presence of paired-pulse facilitation, frequency-dependent short-term facilitation and sensitivity to the mGluR agonist DCG-IV, which blocks glutamate release from the MF but not from the associational-commissural fibers (Kamiya et al., 1996; Yeckel et al., 1999; Kirschstein et al., 2004; Nicoll and Schmitz, 2005) . When fEPSPs were evoked with pairedpulse stimulation (100 ms apart), fEPSPs exhibited a pronounced facilitation of 197.4 Ϯ 14.6% (n ϭ 16 slices). In addition, when the stimulation frequency was increased from 0.05 to 1 Hz, fEPSPs exhibited a marked frequency-dependent facilitation of 246.3 Ϯ 26.3% (n ϭ 8 slices) (Fig.  5 ). Finally, as described (Kamiya et al., 1996; Yeckel et al., 1999) , bath application of DCG-IV reduced the amplitude of fEPSPs measured at 0.05 Hz to 38.9 Ϯ 5.5% (n ϭ 9 slices) (Fig. 5) . Bath application of CGP54626A (2 M) had no significant effect on fEPSP peak amplitudes (control: 100 Ϯ 19.5%, n ϭ 7 slices; CGP54626A: 98.9 Ϯ 18.3%, n ϭ 7 slices), in keeping with patch-clamp experiments showing that ambient levels of GABA do not tonically activate GABA B heteroreceptors (Fig. 3D,E) .
To induce heterosynaptic depression at MF synapses we placed a second stimulating electrode into the dentate gyrus. The position of this electrode and the stimulus intensity were adjusted such that two independent MF pathways could be stimulated (Fig. 6 A) . Pathway one was stimulated at a regular interval of 10 s to evoke MF test fEPSPs (S1). Every tenth stimulus was preceded Ϫ/Ϫ mice (WT: 78.6 Ϯ 2.6% inhibition, n ϭ 7; 1b Ϫ/Ϫ : 75.6 Ϯ 3.7% inhibition, n ϭ 6; 1a Ϫ/Ϫ : 36.4 Ϯ 7.3% inhibition, n ϭ 10, ***p Ͻ 0.001, 1a
Ϫ/Ϫ compared with WT and 1b Ϫ/Ϫ , ANOVA/Scheffe post hoc test). The inhibitory effect of baclofen was blocked by the GABA B receptor antagonist CGP54626A (CGP, 1 M). As a control, adenosine (100 M) efficiently reduced the peak amplitudes of EPSCs in all genotypes (WT: 87.7 Ϯ 1.6% inhibition, n ϭ 6; 1a Ϫ/Ϫ : 80.4% Ϯ 4.4% inhibition, n ϭ 8; 1b Ϫ/Ϫ : 85.7 Ϯ 2.2% inhibition, n ϭ 4). Current traces in A show averages of 10 successive EPSCs (calibration: 20 ms/100 pA). C, Inhibition of glutamate release by different concentrations of baclofen. In 1a Ϫ/Ϫ mice, baclofen was ineffective in inhibiting glutamate release at 0.1 M (n ϭ 5). At higher concentrations, baclofen was always less effective in inhibiting glutamate release in 1a Ϫ/Ϫ mice compared with WT or 1b Ϫ/Ϫ mice (1 M,1a Ϫ/Ϫ :24Ϯ 8.3% inhibition, n ϭ 5, *p Ͻ 0.05, 1a Ϫ/Ϫ compared with WT and 1b Ϫ/Ϫ ; 50 M, 1a Ϫ/Ϫ : 38.4 Ϯ 6.6% inhibition, n ϭ 5, ***p Ͻ 0.001, 1a Ϫ/Ϫ compared with WT and 1b Ϫ/Ϫ , ANOVA/Scheffe post hoc test). In WT and 1b Ϫ/Ϫ mice, baclofen reduced the peak amplitude of EPSCs to the same extent at 0.1 M (WT: 26.5 Ϯ 3.4% inhibition, n ϭ 4; 1b Ϫ/Ϫ : 23.4 Ϯ 6.1% inhibition, n ϭ 4), 1 M (WT: 57.2 Ϯ 5.6% inhibition, n ϭ 4; 1b Ϫ/Ϫ : 50.1 Ϯ 8.9% inhibition, n ϭ 4), and 50 M (WT: 94.8 Ϯ 2.6% inhibition, n ϭ 4; 1b Ϫ/Ϫ : 94.2 Ϯ 2.2% inhibition, n ϭ 4). D, E, Lack of evidence for a tonic activity of GABA B heteroreceptors at MF boutons. D, Evoked EPSCs of a WT CA3 pyramidal neuron recorded in the absence and presence of CGP54626A (1 M). E, Summary histogram showing that in all genotypes the peak amplitudes of evoked EPSCs are not significantly altered in the presence of CGP54626A (WT: 98.2 Ϯ 4.5%, n ϭ 6; 1a Ϫ/Ϫ : 100.9 Ϯ 9.0%, n ϭ 6; 1b Ϫ/Ϫ : 102.8 Ϯ 6.1%, n ϭ 5). Values are means Ϯ SEM.
by a conditioning train of 20 stimuli at 100 Hz on pathway two (S2). The two pathways were stimulated 200 ms apart. To prevent interference from presynaptic opioid and A1 adenosine receptors, heterosynaptic depression was measured in the presence of the antagonists naloxone and DPCPX. Under these conditions a marked GABA B receptor-mediated heterosynaptic depression is observed; only at stronger MF activation levels a direct activation of presynaptic mGluRs through spillover of glutamate will occur (Vogt and Nicoll, 1999) . In WT mice, the amplitudes of test fEPSPs evoked after a train on pathway two (conditioned fEPSPs, closed circles) were significantly reduced by 25.7 Ϯ 3.3% ( p Ͻ 0.01, n ϭ 6 slices) compared with fEPSPs measured in the absence of a conditioning train (unconditioned fEPSPs) (Fig. 6 B, E , open circles). CGP54626A largely or totally inhibited the reduction of conditioned fEPSP amplitudes (Fig. 6 B, E) , confirming that heterosynaptic depression was mainly mediated by GABA B receptors. No GABA B -mediated heterosynaptic depression was detectable in 1a Ϫ/Ϫ mice (conditioned fEPSPs reduced by 2.5 Ϯ 1.4%, p ϭ 0.20, n ϭ 6 slices) and accordingly, CGP54626A had no effect on fEPSPs (Fig. 6C,E) . In contrast, we observed a significant heterosynaptic depression in 1b Ϫ/Ϫ mice (conditioned fEPSP amplitudes reduced by 26.2 Ϯ 2.8%, n ϭ 7 slices; p Ͻ 0.001), which was markedly reduced or abolished by CGP54626A (Fig. 6 D, E) . Confirming that our recordings relate to MF transmission, fEPSPs were always inhibited by application of DCG-IV (Fig. 6 B-D) . Of note, the amplitudes of unconditioned fEPSPs in WT and 1b Ϫ/Ϫ mice were increased in the presence of CGP54626A (Fig.  6 B, D, open circles) , suggesting that the GABA released by the conditioning train lasts long enough to significantly inhibit unconditioned fEPSPs during the 90 s preceding the next conditioning train. In support of this, we found that CGP54626A was without effect on unconditioned fEPSP amplitudes in the absence of the conditioning train (control: 100 Ϯ 18.6%, n ϭ 8 slices; CGP54626A: 100.8 Ϯ 19.1%, n ϭ 8 slices). CGP54626A had no Ϫ/Ϫ and 1b Ϫ/Ϫ mice compared with WT mice (WT: 255.9 Ϯ 23.8 pA, n ϭ 6; 1a Ϫ/Ϫ : 112.8 Ϯ 17.5 pA, n ϭ 7; 1b Ϫ/Ϫ : 130.3 Ϯ 31.9 pA, n ϭ 7; *p Ͻ 0.05, 1a Ϫ/Ϫ and 1b Ϫ/Ϫ compared with WT, ANOVA/Scheffe post hoc test). Control adenosine-induced K ϩ currents were similar in all genotypes (WT: 79.4 Ϯ 15.2 pA, n ϭ 6; 1a Ϫ/Ϫ : 57.1 Ϯ 12.7 pA, n ϭ 7; 1b Ϫ/Ϫ : 64.0 Ϯ 16.5 pA, n ϭ 7), showing that effector K ϩ channels are not altered in 1a Ϫ/Ϫ and 1b Ϫ/Ϫ mice. C, Normalized K ϩ current amplitudes in response to increasing concentrations of baclofen. The maximal K ϩ current amplitude for each concentration was normalized to the mean maximal K ϩ current amplitude recorded from WT neurons at a saturating concentration of baclofen (100 M). In 1a Ϫ/Ϫ and 1b Ϫ/Ϫ mice, the amplitude of baclofen-induced K ϩ was significantly reduced compared with WT mice at 100 M (WT: 100 Ϯ 13.6%, n ϭ 5; 1a Ϫ/Ϫ : 63.7 Ϯ 7.7%, n ϭ 8; 1b Ϫ/Ϫ : 58.7 Ϯ 9.1%, n ϭ 5; *p Ͻ 0.05, 1a
Ϫ/Ϫ and 1b Ϫ/Ϫ compared with WT, ANOVA/Scheffe post hoc test). Baclofen-induced K ϩ current amplitudes were not statistically different between genotypes at concentrations of 0.3 M (WT: 3.6 Ϯ 0.9%, n ϭ 5; 1a Ϫ/Ϫ : 3.6 Ϯ 0.6%, n ϭ 4; 1b Ϫ/Ϫ : 0.8 Ϯ 0.2%, n ϭ 4), 1 M (WT: 7.4 Ϯ 2%, n ϭ 5; 1a Ϫ/Ϫ : 5.7 Ϯ 1.1%, n ϭ 5; 1b Ϫ/Ϫ : 2.4 Ϯ 0.8%, n ϭ 4), and 10 M (WT: 21.7 Ϯ 3.5%, n ϭ 5; 1a Ϫ/Ϫ : 19.5 Ϯ 3.4%, n ϭ 6; 1b Ϫ/Ϫ : 15.5 Ϯ 2.9%, n ϭ 5). Values are means Ϯ SEM. effect on unconditioned fEPSP amplitudes in 1a Ϫ/Ϫ mice, in agreement with a lack of functional GABA B heteroreceptors in these mice (Fig. 6C) . In summary, our experiments show that exclusively GABA B(1a,2) receptors mediate heterosynaptic depression at MF-CA3 synapses.
Late IPSCs are detectable in WT mice but not in 1a
؊/؊ and 1b ؊/؊ mice GABA B(1a,2) and GABA B(1b,2) receptors produce K ϩ -currents of similar amplitude in response to pharmacological activation with baclofen (Fig. 4) . However, it remains possible that GABA B(1a,2) and GABA B(1b,2) receptors produce distinct postsynaptic responses following physiological activation, due to local differences in their somatodendritic abundance. In the hippocampus, synaptically released GABA induces Cl Ϫ -dependent early IPSCs and K ϩ -dependent late IPSCs that are mediated by GABA A and GABA B receptors, respectively (Misgeld et al., 1995; Lüscher et al., 1997) . We simultaneously recorded early and late IPSCs in WT, 1a Ϫ/Ϫ , and 1b
mice. The early IPSC allowed us to verify that stimulation of the MF pathway provoked GABA release in all of our recordings. The amplitude of the late IPSC was used to quantify the extent of GABA B receptor activation in response to synaptically released GABA. Three stimuli at 100 Hz reliably evoked early and late IPSCs in WT mice. The occurrence of late IPSCs was prevented in the presence of CGP54626A, confirming that the late IPSCs are mediated by GABA B receptors ( Fig. 7 A, D) . No late IPSCs were detectable in 1a Ϫ/Ϫ and 1b Ϫ/Ϫ mice, although early IPSCs were always induced (Fig. 7B-D) . This suggests that the reduction of functional postsynaptic GABA B receptors seen in 1a
Ϫ/Ϫ and 1b Ϫ/Ϫ mice after pharmacological stimulation (Fig. 4) leads to subthreshold late IPSCs under physiological conditions. Figure 6 . GABA B -mediated heterosynaptic depression at MF-CA3 pyramidal neuron synapses. A, Two electrodes (S1, S2) positioned in the dentate gyrus were used to stimulate two independent pathways. A third electrode in the CA3 stratum lucidum was used to record MF fEPSPs. Pathway 1 was stimulated at a regular interval of 10 s to evoke test fEPSPs (S1, unconditioned response). Pathway 2 was stimulated 200 ms before every tenth test stimulus with a train of 20 stimuli at 100 Hz (S2, conditioned responses). B, GABA B -mediated heterosynaptic depression in slices of WT mice. The amplitudes of fEPSPs plotted over time (bottom) and average traces (top) are shown. The amplitudes of fEPSPs preceded by a train (closed circles, red traces) were reduced compared with those of fEPSPs not preceded by a train (open circles, black traces). Heterosynaptic depression was largely inhibited or lost in the presence of CGP54626A (CGP; 2 M). Average fEPSP traces are shown in the absence (1) and the presence (2) of CGP54626A (stimulation artifacts were removed). C, GABA B -mediated heterosynaptic depression was absent in slices of 1a Ϫ/Ϫ mice. The amplitudes of conditioned fEPSPs were similar to those of unconditioned fEPSPs. D, GABA B -mediated heterosynaptic depression in slices of 1b Ϫ/Ϫ mice was similar to that in WT mice and inhibited by CGP54626A. Note that CGP54626A also increased the amplitude of unconditioned fEPSPs in WT and 1b Ϫ/Ϫ mice but not in 1a Ϫ/Ϫ mice (B-D). In all genotypes, fEPSPs were inhibited by DCG-IV (2 M). E, Summary histogram of GABA B -mediated heterosynaptic depression. The amplitudes 4 of conditioned fEPSPs were normalized to amplitudes of unconditioned fEPSPs in the absence (baseline) and presence of CGP54626A. Significant CGP54626A-sensitive heterosynaptic depression was observed in WT mice (baseline: 74.3 Ϯ 4%, n ϭ 6 slices; CGP54626A: 100.8 Ϯ 2.7%, n ϭ 6 slices; **p Ͻ 0.01, two-tailed paired Student's t test) and 1b Ϫ/Ϫ mice (baseline: 73.8 Ϯ 2.8%, n ϭ 7 slices; CGP54626A: 95 Ϯ 3.7%, n ϭ 7 slices; **p Ͻ 0.01) but not in 1a Ϫ/Ϫ mice (baseline: 97.5 Ϯ 1.4%, n ϭ 6 slices; CGP54626A: 99.4 Ϯ 1.3%, n ϭ 6 slices; p ϭ 0.32). The ANOVA/Scheffe post hoc test was used for the comparison of genotypes (***p Ͻ 0.001, normalized conditioned fEPSPs in 1a
Ϫ/Ϫ compared with WT and 1b Ϫ/Ϫ mice). Values are means Ϯ SEM.
exact reason for presynaptic inhibition following pharmacological activation with baclofen is unknown. However, our results support that the spatial segregation of GABA B1 isoforms at MF terminals is sufficient to produce a strictly subtype-specific heteroreceptor response under physiological conditions. At other glutamatergic synapses baclofen also produces a significant level of presynaptic inhibition through GABA B(1b,2) heteroreceptors (Shaban et al., 2006; Vigot et al., 2006; . We expect that under physiological conditions exclusively GABA B(1a,2) receptors mediate heteroreceptor function at those synapses as well. Heterosynaptic depression at MF-CA3 pyramidal neuron synapses is thought to play an important role in regulating mnemonic processes (Jin and Chavkin, 1999; Vogt and Nicoll, 1999; Vida and Frotscher, 2000; Chandler et al., 2003) . Heterosynaptic depression increases the sparseness of input signals to CA3 pyramidal cells, thereby enhancing the storage capacity of the CA3 network. Overt memory deficits in hippocampus-dependent memory tasks in 1a Ϫ/Ϫ mice (Vigot et al., 2006; Jacobson et al., 2007) may therefore relate, at least in part, to the disinhibition of MF inputs and the ensuing failure to store or recall memory traces. In addition, the control of GABA B1a -mediated inhibition at MF boutons may be important for regulating synaptic plasticity and limbic seizure prevention, since these processes were also shown to be controlled by GABA B heteroreceptors (Vogt and Nicoll, 1999; Chandler et al., 2003) .
We found that baclofen induces similar maximal K ϩ currents in CA3 neurons of 1a Ϫ/Ϫ and 1b Ϫ/Ϫ mice. Given the surplus of GABA B1b protein at dendritic sites opposite to MF terminals, it may appear surprising that the maximal K ϩ currents induced by GABA B(1b,2) receptors are not larger than those induced by GABA B(1a,2) receptors. However, caution should be exerted when comparing the ultrastructural data with the electrophysiological data. On the one hand, the GABA B receptors included in the ultrastructural analysis may not necessarily be coupled to K ϩ channels. For example, it is conceivable that a larger fraction of GABA B(1a,2) receptors is colocalized with Kir3-type K ϩ channels, rendering their coupling to effector channels more efficient (Karschin, 1999) . Future studies, for example using high-resolution immunocytochemical techniques (Kulik et al., 2006) , will have to address whether GABA B1 isoforms exhibit differences in the colocalization with Kir3-type K ϩ channel subunits. On the other hand, baclofen probably mostly activates K ϩ currents via somatodendritic GABA B receptors remote from MF synapses, and these receptors were excluded from the ultrastructural analysis. It is possible that the relative abundance of GABA B(1a,2) and GABA B(1b,2) receptors differs between dendritic spines and shafts, similar as observed in CA1 pyramidal neurons where GABA B1a protein does not efficiently enter the spines (Vigot et al., 2006) . It further could be argued that the downregulation of GABA B1a protein levels during early postnatal development (Malitschek et al., 1998; Fritschy et al., 1999) accounts for the difference between the morphological and electrophysiological data. However, ruling out this possibility, all our experiments were performed with mice 3 weeks of age or older, when GABA B1a and GABA B1b protein levels remain stable (Malitschek et al., 1998) . While many factors can contribute to the difference between the ultrastructural data of spines and the electrophysiological responses recorded for the soma of CA3 pyramidal neurons, our data further consolidate that the relative contributions of GABA B1a and GABA B1b subunits to the pool of GABA B receptors coupled to effector K ϩ channels varies in between neurons (Ulrich and Bettler, 2007). Importantly, a physiological activation of somatodendritic GABA B receptors by synaptically released GABA does not produce a segregation of GABA B(1a,2) and GABA B(1b,2) responses in CA3 pyramidal neurons, in contrast to the findings with cortical neurons (Huang, 2006; Pérez-Garci et al., 2006) .
In conclusion, our results are consistent with the proposal that independent regulation of expression and distribution of GABA B receptor subtypes enables neurons to dynamically adjust GABA B signaling at axonal and dendritic effectors. The observation that GABA B1a and GABA B1b cannot compensate for each other in response to synaptically released GABA is important from a pharmaceutical perspective. The existence of two functionally distinct GABA B receptor subtypes enables a more selective interference with the GABA B receptor system, which may be of therapeutic benefit for the treatment of neurological and psychiatric disorders (Tiao et al., 2008) .
